nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—gestational diabetes	0.873	1	CbGaD
Pomalidomide—ABCB1—Glyburide—gestational diabetes	0.0566	0.625	CbGbCtD
Pomalidomide—CYP3A4—Glyburide—gestational diabetes	0.0339	0.375	CbGbCtD
Pomalidomide—Thalidomide—TNF—gestational diabetes	0.00464	1	CrCbGaD
Pomalidomide—TNF—vagina—gestational diabetes	0.0035	0.153	CbGeAlD
Pomalidomide—CRBN—islet of Langerhans—gestational diabetes	0.00315	0.138	CbGeAlD
Pomalidomide—CRBN—embryo—gestational diabetes	0.00305	0.133	CbGeAlD
Pomalidomide—CRBN—uterus—gestational diabetes	0.00205	0.0897	CbGeAlD
Pomalidomide—CRBN—adipose tissue—gestational diabetes	0.00201	0.0877	CbGeAlD
Pomalidomide—CRBN—vagina—gestational diabetes	0.00167	0.0729	CbGeAlD
Pomalidomide—CRBN—head—gestational diabetes	0.00154	0.0673	CbGeAlD
Pomalidomide—PTGS2—Nicotinamide salvaging—NAMPT—gestational diabetes	0.00144	0.168	CbGpPWpGaD
Pomalidomide—PTGS2—islet of Langerhans—gestational diabetes	0.000858	0.0374	CbGeAlD
Pomalidomide—PTGS2—embryo—gestational diabetes	0.00083	0.0362	CbGeAlD
Pomalidomide—PTGS2—Nicotinate metabolism—NAMPT—gestational diabetes	0.000766	0.0895	CbGpPWpGaD
Pomalidomide—TNF—Transcription factor regulation in adipogenesis—ADIPOQ—gestational diabetes	0.000582	0.068	CbGpPWpGaD
Pomalidomide—TNF—Type II diabetes mellitus—ADIPOQ—gestational diabetes	0.000582	0.068	CbGpPWpGaD
Pomalidomide—PTGS2—uterus—gestational diabetes	0.000559	0.0244	CbGeAlD
Pomalidomide—PTGS2—adipose tissue—gestational diabetes	0.000547	0.0239	CbGeAlD
Pomalidomide—ABCB1—islet of Langerhans—gestational diabetes	0.000531	0.0232	CbGeAlD
Pomalidomide—ABCB1—embryo—gestational diabetes	0.000513	0.0224	CbGeAlD
Pomalidomide—PTGS2—vagina—gestational diabetes	0.000455	0.0199	CbGeAlD
Pomalidomide—PTGS2—head—gestational diabetes	0.00042	0.0183	CbGeAlD
Pomalidomide—TNF—Transcription factor regulation in adipogenesis—LEP—gestational diabetes	0.000362	0.0423	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—RETN—gestational diabetes	0.000359	0.0419	CbGpPWpGaD
Pomalidomide—ABCB1—uterus—gestational diabetes	0.000346	0.0151	CbGeAlD
Pomalidomide—ABCB1—adipose tissue—gestational diabetes	0.000338	0.0148	CbGeAlD
Pomalidomide—ABCB1—vagina—gestational diabetes	0.000281	0.0123	CbGeAlD
Pomalidomide—ABCB1—head—gestational diabetes	0.00026	0.0113	CbGeAlD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—ADIPOQ—gestational diabetes	0.000214	0.025	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—MBL2—gestational diabetes	0.00018	0.021	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—NAMPT—gestational diabetes	0.000172	0.0201	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase II conjugation—GGCT—gestational diabetes	0.000172	0.02	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—GCK—gestational diabetes	0.000148	0.0172	CbGpPWpGaD
Pomalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—NAMPT—gestational diabetes	0.000146	0.0171	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—FGF2—gestational diabetes	0.000142	0.0166	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—ADIPOQ—gestational diabetes	0.000141	0.0164	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—GCK—gestational diabetes	0.000139	0.0162	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—LEP—gestational diabetes	0.000133	0.0155	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—FGF2—gestational diabetes	0.000132	0.0154	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—GCK—gestational diabetes	0.000129	0.015	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—TNF—gestational diabetes	0.000116	0.0136	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—AR—gestational diabetes	0.000105	0.0123	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—GGCT—gestational diabetes	0.0001	0.0117	CbGpPWpGaD
Pomalidomide—CYP1A2—Tryptophan metabolism—CYP19A1—gestational diabetes	0.0001	0.0117	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—LEP—gestational diabetes	9.43e-05	0.011	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—FGF2—gestational diabetes	9.41e-05	0.011	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—AR—gestational diabetes	8.92e-05	0.0104	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—LEP—gestational diabetes	8.73e-05	0.0102	CbGpPWpGaD
Pomalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	8.11e-05	0.00948	CbGpPWpGaD
Pomalidomide—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	8e-05	0.00935	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GGCT—gestational diabetes	7.74e-05	0.00905	CbGpPWpGaD
Pomalidomide—CYP3A4—Tryptophan metabolism—CYP19A1—gestational diabetes	7.74e-05	0.00904	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—LEP—gestational diabetes	6.58e-05	0.00769	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	6.57e-05	0.00768	CbGpPWpGaD
Pomalidomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—gestational diabetes	6.26e-05	0.00731	CbGpPWpGaD
Pomalidomide—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—gestational diabetes	6.18e-05	0.00722	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—GCK—gestational diabetes	5.87e-05	0.00686	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—LEP—gestational diabetes	5.83e-05	0.00682	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—gestational diabetes	5.73e-05	0.0067	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AR—gestational diabetes	5.52e-05	0.00645	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—gestational diabetes	5.36e-05	0.00627	CbGpPWpGaD
Pomalidomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—gestational diabetes	5.07e-05	0.00593	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—FGF2—gestational diabetes	4.88e-05	0.0057	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—ADIPOQ—gestational diabetes	4.83e-05	0.00565	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AR—gestational diabetes	3.91e-05	0.00457	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP19A1—gestational diabetes	3.49e-05	0.00408	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP19A1—gestational diabetes	3.44e-05	0.00402	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—gestational diabetes	3.41e-05	0.00399	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—gestational diabetes	3.25e-05	0.00379	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—gestational diabetes	3.25e-05	0.00379	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GGCT—gestational diabetes	3.03e-05	0.00354	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FGF2—gestational diabetes	3.02e-05	0.00352	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—LEP—gestational diabetes	3e-05	0.00351	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—gestational diabetes	2.7e-05	0.00315	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP19A1—gestational diabetes	2.69e-05	0.00315	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP19A1—gestational diabetes	2.66e-05	0.00311	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GLS2—gestational diabetes	2.65e-05	0.0031	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—gestational diabetes	2.64e-05	0.00308	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—gestational diabetes	2.37e-05	0.00277	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—FGF2—gestational diabetes	2.28e-05	0.00266	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—GCK—gestational diabetes	2.18e-05	0.00255	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GGCT—gestational diabetes	2.15e-05	0.00251	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—gestational diabetes	2.14e-05	0.0025	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—RBP4—gestational diabetes	1.93e-05	0.00226	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GLS2—gestational diabetes	1.88e-05	0.0022	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—gestational diabetes	1.84e-05	0.00215	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NAMPT—gestational diabetes	1.73e-05	0.00203	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GCK—gestational diabetes	1.72e-05	0.00201	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GGCT—gestational diabetes	1.72e-05	0.00201	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GLS2—gestational diabetes	1.5e-05	0.00175	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NAMPT—gestational diabetes	1.45e-05	0.0017	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GCK—gestational diabetes	1.44e-05	0.00169	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—gestational diabetes	1.34e-05	0.00157	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GGCT—gestational diabetes	1.32e-05	0.00155	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—gestational diabetes	1.3e-05	0.00152	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GLS2—gestational diabetes	1.16e-05	0.00135	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP19A1—gestational diabetes	1.06e-05	0.00123	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NAMPT—gestational diabetes	1.03e-05	0.0012	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GCK—gestational diabetes	1.02e-05	0.0012	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NAMPT—gestational diabetes	8.22e-06	0.00096	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GCK—gestational diabetes	8.17e-06	0.000954	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP19A1—gestational diabetes	7.48e-06	0.000874	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGF2—gestational diabetes	6.7e-06	0.000782	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NAMPT—gestational diabetes	6.34e-06	0.000741	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GCK—gestational diabetes	6.3e-06	0.000737	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP19A1—gestational diabetes	5.97e-06	0.000698	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP19A1—gestational diabetes	4.61e-06	0.000539	CbGpPWpGaD
